TPIV : Summary for TAPIMMUNE INC - Yahoo Finance

U.S. Markets closed

TapImmune, Inc. (TPIV)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.26+0.09 (+2.16%)
At close: 4:00PM EDT
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close4.17
Bid0.00 x
Ask6.22 x 200
Day's Range4.16 - 4.26
52 Week Range3.32 - 9.12
Avg. Volume39,953
Market Cap35.95M
PE Ratio (TTM)-5.95
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • TapImmune Announces Change in Management and Board of Directors
    PR Newswire14 hours ago

    TapImmune Announces Change in Management and Board of Directors

    JACKSONVILLE, Fla., April 28, 2017 /PRNewswire/ -- TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, has announced that on April 27, 2017, Dr. John Bonfiglio resigned as Chief Operating Officer, President and director of TapImmune, Inc. to pursue other opportunities. Speaking for the Board of Directors, Chairman and CEO of TapImmune Dr. Glynn Wilson stated, "We have been fortunate to have John serve the Company initially as a consultant and subsequently as an officer and director.

  • Benzinga2 days ago

    Drug Trials Heating Up In The Breast and Ovarian Cancer Treatment Space

    The next generation of breast and ovarian cancer treatment is attacking the deadly disease from all angles. That is no more evident than in the glut of pharmaceutical companies racing to develop, test, ...

  • Marketwired10 days ago

    NetworkNewsWire Announces Publication Highlighting Advances in Cancer Therapy

    NetworkNewsWire , a multifaceted financial news and publishing company, today announces the publication of an editorial featuring TapImmune, Inc. , an NNW client focused on leading the field of oncology ...